BlackRock, Inc. 13D and 13G filings for Coherus BioSciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-24 09:46 am Purchase | 2023-12-31 | 13G | Coherus BioSciences, Inc. CHRS | BlackRock Inc. BLK | 12,074,695 10.800% | 428,860 (+3.68%) | Filing |
| 2023-10-06 2:34 pm Sale | 2023-09-30 | 13G | Coherus BioSciences, Inc. CHRS | BlackRock Inc. BLK | 11,645,835 10.900% | -2,433,066 (-17.28%) | Filing |
| 2023-01-26 08:52 am Unchanged | 2022-12-31 | 13G | Coherus BioSciences, Inc. CHRS | BlackRock Inc. BLK | 14,078,901 18.100% | 0 (Unchanged) | Filing |
| 2023-01-20 09:43 am Purchase | 2022-12-31 | 13G | Coherus BioSciences, Inc. CHRS | BlackRock Inc. BLK | 14,078,901 18.100% | 2,160,046 (+18.12%) | Filing |
| 2022-01-27 5:14 pm Unchanged | 2021-12-31 | 13G | Coherus BioSciences, Inc. CHRS | BlackRock Inc. BLK | 11,918,855 15.500% | 0 (Unchanged) | Filing |
| 2022-01-26 09:16 am Purchase | 2021-12-31 | 13G | Coherus BioSciences, Inc. CHRS | BlackRock Inc. BLK | 11,918,855 15.500% | 1,390,505 (+13.21%) | Filing |
| 2021-01-26 2:22 pm Purchase | 2020-12-31 | 13G | Coherus BioSciences, Inc. CHRS | BlackRock Inc. BLK | 10,528,350 14.600% | 369,351 (+3.64%) | Filing |
| 2020-06-09 4:32 pm Purchase | 2020-05-31 | 13G | Coherus BioSciences, Inc. CHRS | BlackRock Inc. BLK | 10,158,999 14.300% | 4,486,780 (+79.10%) | Filing |
| 2020-02-05 11:25 am Purchase | 2019-12-31 | 13G | Coherus BioSciences, Inc. CHRS | BlackRock Inc. BLK | 5,672,219 8.100% | 949,801 (+20.11%) | Filing |